SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model

Respirology : Official Journal of the Asian Pacific Society of Respirology
Trung The VanSaburo Sone

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive neoplasm of the mesothelium with high chemotherapeutic resistance. In this study, the preclinical therapeutic activity of the multiple tyrosine kinase inhibitor, SU6668, against MPM was examined. Two human MPM cell lines with different pro-angiogenic cytokine expression, Y-MESO-14 cells that express high levels of vascular endothelial growth factor (VEGF) and MSTO-211H cells that express high levels of basic fibroblast growth factor (bFGF), were orthotopically inoculated into the thoracic cavities of mice with severe combined immunodeficiency. The mice with MPM were treated or not treated with SU6668 (200 mg/kg/day). SU6668 abrogated the proliferation of endothelial cells stimulated by VEGF or bFGF, but did not directly affect the growth of human MPM cells in vitro. In this orthotopic implantation model, treatment with SU6668 effectively reduced tumour weight and pleural effusion volumes, in association with inhibition of the growth of tumour vasculature. More importantly, treatment with SU6668 significantly prolonged survival time in mice with MPM. These findings suggest that SU6668 has a promising therapeutic effect on the progression of MPM in vivo through its anti-angiog...Continue Reading

References

Mar 1, 1972·Annals of Surgery·J Folkman
Aug 21, 1996·Journal of the National Cancer Institute·Y TakahashiL M Ellis
Jun 1, 1997·The Journal of Pathology·S Kumar-SinghE Van Marck
Feb 23, 1999·British Journal of Cancer·J PetoE Negri
Aug 19, 1999·The Journal of Pathology·S Kumar-SinghE Van Marck
Sep 15, 2001·British Journal of Cancer·J G EdwardsK J O'Byrne
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas J VogelzangPaolo Paoletti
Sep 5, 2003·International Journal of Clinical Oncology·Yasufumi Sato
Oct 13, 2004·The Oncologist·Maitreyee HazarikaRichard Pazdur
Nov 20, 2004·International Journal of Cancer. Journal International Du Cancer·Shizuo MachidaMitsuaki Suzuki
Jun 14, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Priya Kumar, Robert A Kratzke
Dec 20, 2005·American Journal of Industrial Medicine·Takehiko MurayamaNorio Kurumatani
Mar 31, 2007·Nature Reviews. Drug Discovery·Judah Folkman
Apr 27, 2007·Langenbeck's Archives of Surgery·M E EichhornC J Bruns
May 31, 2007·Nature Clinical Practice. Oncology·Athanasios Tsiouris, Robin K Walesby
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicolas J DickgreberMichael Thomas
Mar 26, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Joyce E NuttJohn Lunec
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenji IkutaSaburo Sone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Nicholas J VogelzangPaolo Paoletti
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Anna K NowakMichael J Byrne
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Scott A LaurieLesley Seymour
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Thierry JahanHedy L Kindler
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Nicholas P CampbellHedy L Kindler
© 2021 Meta ULC. All rights reserved